Related Experiment Video
Updated: May 22, 2026
06:00
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Kinesin spindle protein SiRNA slows tumor progression
Emanuele Marra1, Fabio Palombo, Gennaro Ciliberto
1Takis srl, Rome, Italy.
Journal of Cellular Physiology
|May 4, 2012
Summary
Intratumoral electro-transfer of small interfering RNA (siRNA) targeting kinesin spindle protein (KSP) effectively reduced tumor growth. This RNA interference (RNAi) approach shows promise for novel cancer therapeutics.
Area of Science:
- Molecular Biology
- Oncology
- Biotechnology
Background:
- Kinesin spindle protein (KSP) is crucial for mitosis, regulating centrosome separation and spindle assembly.
- KSP inhibition causes mitotic arrest and cell death, making it a target for anticancer drug development.
- RNA interference (RNAi) offers a potential strategy to target cancer-related molecular pathways.
Purpose of the Study:
- To establish an efficient method for intratumoral delivery of small interfering RNA (siRNA).
- To evaluate the efficacy of siRNA targeting KSP for cancer treatment.
- To assess the feasibility of using intratumor electro-transfer of RNA therapeutics (IERT) for gene knockdown.
Main Methods:
- Developed and tested siRNA duplexes targeting luciferase (surrogate) and KSP.
- Utilized intratumor electro-transfer of RNA therapeutics (IERT) for siRNA delivery into pre-established tumors.
- Assessed gene knockdown efficiency and tumor growth inhibition.
Main Results:
- Intratumoral electro-transfer of siRNA enabled efficient, albeit transient, gene knockdown.
- KSP-specific siRNA significantly reduced the outgrowth of subcutaneous melanoma and ovarian cancer lesions.
- Luciferase-targeted siRNA served as an effective surrogate marker.
Conclusions:
- Intratumoral electro-transfer of siRNA is a feasible delivery method for RNA therapeutics.
- KSP-specific siRNA demonstrates significant potential as a novel therapeutic strategy for cancer intervention.
- This RNAi-based approach warrants further investigation for clinical application in oncology.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:45Destabilization of Microtubules
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...